mitomycin has been researched along with Leiomyosarcoma in 13 studies
Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.
Leiomyosarcoma: A sarcoma containing large spindle cells of smooth muscle. Although it rarely occurs in soft tissue, it is common in the viscera. It is the most common soft tissue sarcoma of the gastrointestinal tract and uterus. The median age of patients is 60 years. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p1865)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Following a reported 23% response rate (RR) for mitomycin (M), doxorubicin (A), and cisplatin (P) and preliminary data suggesting a superior RR for dacarbazine (D) + MAP + sargramostim, the Gynecologic Oncology Group (GOG) conducted a phase II trial of DMAP + sargramostim in patients with advanced uterine leiomyosarcoma." | 9.11 | Phase II trial of dacarbazine, mitomycin, doxorubicin, and cisplatin with sargramostim in uterine leiomyosarcoma: a Gynecologic Oncology Group study. ( Blessing, JA; Long, HJ; Sorosky, J, 2005) |
| "Adult patients with advanced leiomyosarcomas received intravenous chemotherapy as outpatients with dacarbazine 750 micrograms/m2, mitomycin 6 mg/m2, doxorubicin 40 mg/m2, and cisplatin 60 mg/m2 on day 0, with granulocyte macrophage colony stimulating factor (GM-CSF, sagramostim) 250 mcg/m2 given s." | 9.10 | Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas. ( Buckner, JC; Edmonson, JH; Mahoney, MR; Marks, RS, 2002) |
| "Because of preliminary observations favoring the use of mitomycin, doxorubicin, and cisplatin (MAP) chemotherapy in leiomyosarcomas, the Gynecologic Oncology Group (GOG) decided to conduct a phase II clinical trial of this combination regimen in patients with advanced disease." | 9.10 | Phase II study of mitomycin, doxorubicin, and cisplatin in the treatment of advanced uterine leiomyosarcoma: a Gynecologic Oncology Group study. ( Blessing, JA; Cohn, DE; Cosin, JA; Edmonson, JH; Miller, DS; Rotmensch, J, 2002) |
| "In all 63 patients were treated monthly with a combination of mitomycin, doxorubicin, and cisplatin, and 27 (43%) experienced objective regression of their advanced sarcomas during a 3-month trial." | 7.67 | Phase II study of a combination of mitomycin, doxorubicin and cisplatin in advanced sarcomas. ( Creagan, ET; Edmonson, JH; Green, SJ; Long, HJ; Richardson, RL, 1985) |
| "Following a reported 23% response rate (RR) for mitomycin (M), doxorubicin (A), and cisplatin (P) and preliminary data suggesting a superior RR for dacarbazine (D) + MAP + sargramostim, the Gynecologic Oncology Group (GOG) conducted a phase II trial of DMAP + sargramostim in patients with advanced uterine leiomyosarcoma." | 5.11 | Phase II trial of dacarbazine, mitomycin, doxorubicin, and cisplatin with sargramostim in uterine leiomyosarcoma: a Gynecologic Oncology Group study. ( Blessing, JA; Long, HJ; Sorosky, J, 2005) |
| "Adult patients with advanced leiomyosarcomas received intravenous chemotherapy as outpatients with dacarbazine 750 micrograms/m2, mitomycin 6 mg/m2, doxorubicin 40 mg/m2, and cisplatin 60 mg/m2 on day 0, with granulocyte macrophage colony stimulating factor (GM-CSF, sagramostim) 250 mcg/m2 given s." | 5.10 | Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas. ( Buckner, JC; Edmonson, JH; Mahoney, MR; Marks, RS, 2002) |
| "Because of preliminary observations favoring the use of mitomycin, doxorubicin, and cisplatin (MAP) chemotherapy in leiomyosarcomas, the Gynecologic Oncology Group (GOG) decided to conduct a phase II clinical trial of this combination regimen in patients with advanced disease." | 5.10 | Phase II study of mitomycin, doxorubicin, and cisplatin in the treatment of advanced uterine leiomyosarcoma: a Gynecologic Oncology Group study. ( Blessing, JA; Cohn, DE; Cosin, JA; Edmonson, JH; Miller, DS; Rotmensch, J, 2002) |
| "A patient with mitomycin-associated hemolytic-uremic syndrome received SPA treatments after her ACE inhibitor, lisinopril, was held." | 3.71 | Hypotensive reaction during staphylococcal protein A column therapy in a patient with anomalous degradation of bradykinin and Des-Arg9-bradykinin after contact activation. ( Adam, A; Eastlund, T; Hammerschmidt, D; Koenigbauer, U; Lepage, Y; Molinaro, G, 2002) |
| "In all 63 patients were treated monthly with a combination of mitomycin, doxorubicin, and cisplatin, and 27 (43%) experienced objective regression of their advanced sarcomas during a 3-month trial." | 3.67 | Phase II study of a combination of mitomycin, doxorubicin and cisplatin in advanced sarcomas. ( Creagan, ET; Edmonson, JH; Green, SJ; Long, HJ; Richardson, RL, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (15.38) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 7 (53.85) | 29.6817 |
| 2010's | 2 (15.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baratti, D | 1 |
| Pennacchioli, E | 1 |
| Kusamura, S | 1 |
| Fiore, M | 1 |
| Balestra, MR | 1 |
| Colombo, C | 1 |
| Mingrone, E | 1 |
| Gronchi, A | 1 |
| Alessanrdro, G | 1 |
| Deraco, M | 1 |
| Baumgartner, JM | 1 |
| Ahrendt, SA | 1 |
| Pingpank, JF | 1 |
| Holtzman, MP | 1 |
| Ramalingam, L | 1 |
| Jones, HL | 1 |
| Zureikat, AH | 1 |
| Zeh, HJ | 1 |
| Bartlett, DL | 1 |
| Choudry, HA | 1 |
| Edmonson, JH | 3 |
| Marks, RS | 1 |
| Buckner, JC | 1 |
| Mahoney, MR | 1 |
| Molinaro, G | 1 |
| Adam, A | 1 |
| Lepage, Y | 1 |
| Hammerschmidt, D | 1 |
| Koenigbauer, U | 1 |
| Eastlund, T | 1 |
| Mohindra, A | 1 |
| Bolderson, E | 1 |
| Stone, J | 1 |
| Wells, M | 1 |
| Helleday, T | 1 |
| Meuth, M | 1 |
| Long, HJ | 2 |
| Blessing, JA | 2 |
| Sorosky, J | 1 |
| Dispenzieri, A | 1 |
| Loprinzi, CL | 1 |
| Yokota, T | 1 |
| Abe, Y | 1 |
| Itoh, J | 1 |
| Kunori, T | 1 |
| Mochizuki, M | 1 |
| Asano, S | 1 |
| Shinya, F | 1 |
| Rajan, DK | 1 |
| Soulen, MC | 1 |
| Clark, TW | 1 |
| Baum, RA | 1 |
| Haskal, ZJ | 1 |
| Shlansky-Goldberg, RD | 1 |
| Freiman, DB | 1 |
| Cosin, JA | 1 |
| Miller, DS | 1 |
| Cohn, DE | 1 |
| Rotmensch, J | 1 |
| Matsumoto, M | 1 |
| Goshima, H | 1 |
| Yamazaki, Y | 1 |
| Kokehara, N | 1 |
| Oota, M | 1 |
| Ishida, N | 1 |
| Itou, F | 1 |
| Richardson, RL | 1 |
| Creagan, ET | 1 |
| Green, SJ | 1 |
| Senapad, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Evaluation of DMAP Plus GM-CSF in the Treatment of Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus[NCT00033644] | Phase 2 | 0 participants | Interventional | 2002-03-31 | Terminated | ||
| Evaluation of Mitomycin, Doxorubicin and Cisplatin in the Treatment of Recurrent or Advanced Uterine Sarcomas[NCT00002993] | Phase 2 | 30 participants (Anticipated) | Interventional | 1997-08-31 | Terminated | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for mitomycin and Leiomyosarcoma
10 other studies available for mitomycin and Leiomyosarcoma
| Article | Year |
|---|---|
Peritoneal sarcomatosis: is there a subset of patients who may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusio | 2010 |
Aggressive locoregional management of recurrent peritoneal sarcomatosis.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Chemo | 2013 |
Hypotensive reaction during staphylococcal protein A column therapy in a patient with anomalous degradation of bradykinin and Des-Arg9-bradykinin after contact activation.
Topics: Acute Disease; Aminopeptidases; Angiotensin-Converting Enzyme Inhibitors; Antineoplastic Combined Ch | 2002 |
A tumour-derived mutant allele of XRCC2 preferentially suppresses homologous recombination at DNA replication forks.
Topics: Base Pair Mismatch; Camptothecin; DNA; DNA Repair; DNA Replication; DNA-Binding Proteins; Female; Ge | 2004 |
Chemotherapy-induced insulin-dependent diabetes mellitus.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Dexamethasone; | 1997 |
Epithelioid leiomyosarcoma of the stomach: report of a case.
Topics: Abdominal Pain; Angiography, Digital Subtraction; Antibiotics, Antineoplastic; Biopsy; Combined Moda | 2000 |
Sarcomas metastatic to the liver: response and survival after cisplatin, doxorubicin, mitomycin-C, Ethiodol, and polyvinyl alcohol chemoembolization.
Topics: Chemoembolization, Therapeutic; Cisplatin; Disease Progression; Doxorubicin; Ethiodized Oil; Female; | 2001 |
[A case of unresectable liver metastasis from leiomyosarcoma of the stomach successfully treated by intra hepato-arterial chemotherapy with Infuse-A-Port].
Topics: Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fluorouracil; Hepatic Artery; Humans; I | 1990 |
Phase II study of a combination of mitomycin, doxorubicin and cisplatin in advanced sarcomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Dru | 1985 |
Chemotherapy for gynecologic malignancies at Siriraj Hospital, Bangkok.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Cyclophosphamid | 1985 |